SI21259B - Farmacevtski pripravki z antibiotičnim delovanjem - Google Patents

Farmacevtski pripravki z antibiotičnim delovanjem Download PDF

Info

Publication number
SI21259B
SI21259B SI200300194A SI200300194A SI21259B SI 21259 B SI21259 B SI 21259B SI 200300194 A SI200300194 A SI 200300194A SI 200300194 A SI200300194 A SI 200300194A SI 21259 B SI21259 B SI 21259B
Authority
SI
Slovenia
Prior art keywords
sodium
potassium
compound
citrate
tribasic
Prior art date
Application number
SI200300194A
Other languages
English (en)
Other versions
SI21259A (sl
Inventor
RAMPOLDI@Luca
PIRRONE@Luca
FACCIN@Sarah
GRASSANO@Alessandro
GURRIERI@Giovanni
Original Assignee
Zambon@Group@S@P@A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27638551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI21259(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zambon@Group@S@P@A filed Critical Zambon@Group@S@P@A
Publication of SI21259A publication Critical patent/SI21259A/sl
Publication of SI21259B publication Critical patent/SI21259B/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Opisana je uporaba določenih soli in amino kislin kot stabilizatorja antibiotika Fosfomicin Trometamola in farmacevtski pripravki ki jih vsebujejo

Claims (7)

1 PATENTNI ZAHTEVKI 1. Uporaba snovi, izbrana izmed: tribaznega natrijevega ali kalijevega citrata monoklislinskega natrijevega ali kalijevega citrata tribaznega natrijevega ali kalijevega fosfata monoklislinskega natrijevega ali kalijevega fosfata natrijevega ali kalijevega karbonata natrijevega ali kalijevega bikarbonata natrijevega ali kalijevega tartrata arginina - lizina ali njihovih mešanic za stabiliziranje Fosfomicin Trometamola.
2. Uporaba spojine kot stabilizatorja po zahtevku 1, označena s tem, daje spojina izbrana izmed tribaznega natrijevega citrata, natrijevega karbonata ali arginina. . Uporaba spojine kot stabilizatorja po zahtevku 1, označena s tem, daje spojina v molskem razmerju glede na vsebnost FT v razponu med 10% in 100%, prednostno med 30% in 70% in bolj prednostno okoli 50%. ι
4. Farmacevtski pripravek, ki vsebuje Fosfomicin Trometamol spojino izbrano izmed: 5 10 tribaznega natrijevega ali kalijevega citrata monoklislinskega natrijevega ali kalijevega citrata tribaznega natrijevega ali kalijevega fosfata - monoklislinskega natrijevega ali kalijevega fosfata natrijevega ali kalijevega karbonata natrijevega ali kalijevega bikarbonata natrijevega ali kalijevega tartrata - arginina lizina ali njihovih mešanic in pomožne snovi za farmacevtsko rabo. 15
5. Pripravek po zahtevku 4, v obliki topnega granulata.
6. Pripravek po zahtevku 5, kjer je vsebovana količina FT za en odmerek 5,631 g· 20
7. Pripravek po zahtevku 1, kjer je snov s stabilizacijskim delovanjem izbrana izmed tribaznega natrijevega citrata, natrijevega karbonata in arginina.
8. Pripravek po zahtevku 1, kjer je snov s stabilizacijskim delovanjem v molskem razmerju glede na vsebnost FT v razponu med 10% in 100%, prednostno med 30% in 70% in bolj prednostno okoli 50%.
SI200300194A 2002-08-01 2003-07-24 Farmacevtski pripravki z antibiotičnim delovanjem SI21259B (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001725A ITMI20021725A1 (it) 2002-08-01 2002-08-01 Composizioni farmaceutiche ad attivita' antibiotica.

Publications (2)

Publication Number Publication Date
SI21259A SI21259A (sl) 2004-02-29
SI21259B true SI21259B (sl) 2012-12-31

Family

ID=27638551

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200300194A SI21259B (sl) 2002-08-01 2003-07-24 Farmacevtski pripravki z antibiotičnim delovanjem

Country Status (29)

Country Link
US (1) US7303755B2 (sl)
JP (1) JP4395338B2 (sl)
KR (1) KR100966977B1 (sl)
AT (1) AT500521B1 (sl)
BE (1) BE1017903A3 (sl)
BR (1) BRPI0302496C1 (sl)
CA (1) CA2434927C (sl)
CH (1) CH696718A5 (sl)
CO (1) CO5480297A1 (sl)
CZ (1) CZ305023B6 (sl)
DE (1) DE10334820B4 (sl)
DK (1) DK178348B1 (sl)
ES (1) ES2224869B1 (sl)
FI (1) FI120080B (sl)
FR (1) FR2852845B1 (sl)
GR (1) GR20030100300A (sl)
HR (1) HRP20030618B1 (sl)
HU (1) HU230575B1 (sl)
IL (1) IL156615A (sl)
IT (1) ITMI20021725A1 (sl)
NL (1) NL1023790C2 (sl)
PL (1) PL209644B1 (sl)
PT (1) PT102995B (sl)
RU (1) RU2333000C2 (sl)
SE (1) SE527466C2 (sl)
SI (1) SI21259B (sl)
SK (1) SK287201B6 (sl)
TR (1) TR200301248A2 (sl)
ZA (1) ZA200305040B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE740685C (de) * 1941-04-11 1943-10-26 Voigt & Haeffner Ag Viertakt-Regelschalter fuer Parallel-, Einzel- und Reihenschaltung von Heizwiderstaenden
ES2244333B1 (es) * 2004-05-18 2006-08-01 Simbec Iberica, Sl Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2482812B1 (en) 2009-10-02 2023-01-11 Boehringer Ingelheim International GmbH Pharmaceutical compositions comprising bi-1356 and metformin
EA021876B1 (ru) * 2010-09-20 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
ES2385158B1 (es) * 2010-12-24 2013-05-28 Arafarma Group, S.A. Composición farmacéutica de fosfomicina
CN102579466A (zh) * 2011-01-10 2012-07-18 王乐 一种磷霉素或磷霉素精氨酸盐与精氨酸的组合物
US8604078B2 (en) * 2011-04-06 2013-12-10 Carlos Picornell Darder Fosfomycin pharmaceutical composition
US20140323443A1 (en) * 2013-04-30 2014-10-30 Fresenius Kabi Usa, Llc Tigecycline formulations
ITTO20130839A1 (it) * 2013-10-16 2015-04-17 C & G Farmaceutici S R L Composizione a base di fosfomicina trometamolo
DE102014218913A1 (de) * 2014-09-19 2016-03-24 Heraeus Medical Gmbh Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver
CN104546689B (zh) * 2015-01-07 2019-01-25 同方药业集团有限公司 一种含有甲硝唑的药物组合物
WO2017111718A1 (en) 2015-12-25 2017-06-29 Yusuf Toktamiş Öğün The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections
CA3147662A1 (en) 2021-02-10 2022-08-10 Labiana Health, S.L. New fosfomycin tablet formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
IT1161974B (it) 1978-02-02 1987-03-18 Italchemi Spa Derivti dell acido cis.i 2 epossipropilfosfonico loro procedimento di preparazione e composizioni farmaceutiche che li contengono
IT1112282B (it) 1978-07-19 1986-01-13 Zambon Spa Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato
IT1124610B (it) 1979-10-18 1986-05-07 Zambo Spa Mono(2-ammonio-2-idrossimetil-1,3-propandiolo) (2r-cis)-(o-metilossiranil)fosfonato
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
CH660305A5 (de) * 1984-10-05 1987-04-15 Schering Spa Wasserloesliche pharmazeutische zusammensetzungen auf der basis von salzen der (-)cis-1,2-epoxypropylphosphonsaeure mit aminosaeuren.
US5182274A (en) * 1988-09-26 1993-01-26 Teijin Limited Stabilized aqueous preparation of active form of vitamin d3
US5191094A (en) 1989-07-27 1993-03-02 Zambon Group S.P.A. Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing
IT1231013B (it) 1989-07-27 1991-11-08 Zambon Spa Mono (2 ammonio 2 idrossimetil 1,3 propandiolo)(2r,cis) 1,2 epossipropil fosfonato avente migliorate caratteristiche di stabilita' e lavorabilita'.
IT1244543B (it) 1991-02-01 1994-07-15 La Fa Re Srl Uso topico della fosfomicina e dei suoi sali nella terapia delle infezioni vaginali e/o uretrali
FR2690340B1 (fr) 1992-04-24 1995-02-24 Scr Newmed Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
CA2153553A1 (en) * 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
JPH09183730A (ja) * 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
DE19712565A1 (de) 1997-03-25 1998-10-01 Thomas W Dr Stief Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes
EP2263654B1 (en) * 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Compositions for improving the oral absorption of antimicrobial agents
US6699505B2 (en) * 2000-10-17 2004-03-02 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by compexing with cyclodextrins
US7378408B2 (en) 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
TW200403240A (en) * 2002-06-28 2004-03-01 Upjohn Co Difluorothioacetamides of oxazolidinones as antibacterial agents

Also Published As

Publication number Publication date
FR2852845A1 (fr) 2004-10-01
HRP20030618B1 (en) 2011-10-31
ZA200305040B (en) 2004-05-11
CZ305023B6 (cs) 2015-04-01
HUP0302441A2 (hu) 2005-07-28
ITMI20021725A1 (it) 2002-10-31
FR2852845B1 (fr) 2006-01-06
AT500521B1 (de) 2007-11-15
DE10334820A1 (de) 2004-03-11
CZ20032096A3 (cs) 2004-03-17
CA2434927C (en) 2011-10-18
BE1017903A3 (fr) 2009-11-03
PL209644B1 (pl) 2011-09-30
KR20040012569A (ko) 2004-02-11
FI120080B (fi) 2009-06-30
NL1023790A1 (nl) 2004-02-03
BRPI0302496C1 (pt) 2021-05-25
AT500521A1 (de) 2006-01-15
SI21259A (sl) 2004-02-29
FI20031078A0 (fi) 2003-07-16
GR20030100300A (el) 2004-04-22
BR0302496A (pt) 2004-08-24
CO5480297A1 (es) 2005-01-28
SE527466C2 (sv) 2006-03-14
CA2434927A1 (en) 2004-02-01
ES2224869B1 (es) 2007-07-01
ES2224869A1 (es) 2005-03-01
JP4395338B2 (ja) 2010-01-06
US7303755B2 (en) 2007-12-04
TR200301248A2 (tr) 2004-02-23
US20040022866A1 (en) 2004-02-05
DE10334820B4 (de) 2020-02-06
KR100966977B1 (ko) 2010-06-30
BRPI0302496B1 (pt) 2015-07-28
SE0302129D0 (sv) 2003-07-25
FI20031078A (fi) 2004-02-02
RU2003124299A (ru) 2005-01-20
CH696718A5 (it) 2007-10-31
SE0302129L (sv) 2004-02-02
IL156615A (en) 2008-11-26
RU2333000C2 (ru) 2008-09-10
SK287201B6 (sk) 2010-03-08
IL156615A0 (en) 2004-01-04
HRP20030618A2 (en) 2004-04-30
NL1023790C2 (nl) 2004-03-10
JP2004067682A (ja) 2004-03-04
SK9762003A3 (en) 2004-02-03
HU0302441D0 (en) 2003-09-29
PL361518A1 (en) 2004-02-09
PT102995B (pt) 2004-07-30
BRPI0302496B8 (pt) 2016-09-13
HU230575B1 (hu) 2017-02-28
PT102995A (pt) 2004-02-27
DK178348B1 (da) 2016-01-04
DK200301097A (da) 2004-02-02

Similar Documents

Publication Publication Date Title
SI21259B (sl) Farmacevtski pripravki z antibiotičnim delovanjem
KR900006827B1 (ko) 구강위생 조성물
MX2010005122A (es) Estabilizacion de radiofarmaceuticos.
JP4948392B2 (ja) 固形薬学的組成物を調製するためのプロセス
ATE300189T1 (de) Herstellung von hochloeslichen und stabilen mineralstoffergaenzungen
US4409233A (en) Highly concentrated preparations of dopa compounds
KR920005978A (ko) 안정화된 고형화학 조성물
CN108578268A (zh) 一种含有溶菌酶的牙膏
JP3772468B2 (ja) L−アスコルビン酸−2−リン酸亜鉛塩及びその製造方法
DK2170920T3 (en) STABLE OF SALTS AND S-adenosylmethionine process for its preparation
JPH0840907A (ja) セファロスポリン注射剤
JPH0154338B2 (sl)
ES2257559T3 (es) Procedimiento para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio.
JP2003206224A5 (sl)
ES443030A1 (es) Procedimiento para la estabilizacion de anhidrido de hidro- genofosfato de calcio contra la reaccion con iones fluor.
JPH01216996A (ja) 安定剤を混ぜて乾燥させることによるセファロスポリン誘導体の安定化法およびセファロスポリン誘導体を含有する安定な組成物
ATE417619T1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung
CA2534259A1 (en) Glycyrrhizin high-concentration preparation
MXPA05008860A (es) Composiciones farmaceuticas estabilizadas de safingol y metodos para utilizar las mismas.
JP2019532927A5 (sl)
JPH06105906A (ja) 透析用剤
US2611732A (en) Compositions containing mixtures of 4-aminosalicylic acid and its basic calcium salt
ES443034A1 (es) Procedimiento para la aplicacion de una capa molecular de a-cido aminofosfonico sobre dihidrato de hidrogenofosfato de calcio.
JPS5832873A (ja) ポリプレニルアミド系化合物含有組成物
JPH0774191B2 (ja) 安定化されたメナジオン重亜硫酸塩組成物

Legal Events

Date Code Title Description
IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20121108